Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO – HBV
166758
post-template-default,single,single-post,postid-166758,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO – HBV

arrowhead-pharmaceuticals

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2 Study of ARO – HBV

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) – WITH Research and Development facilities at University Research Park, today announced that it filed a regulatory submission to begin a Phase 1/2 study of ARO-HBV, which is being developed as a potentially curative therapy for patients with chronic hepatitis B virus (HBV) infection.

Pending approval, Arrowhead intends to proceed with AROHBV1001, a Phase 1/2 single-dose escalation study to evaluate the safety, tolerability, and pharmacokinetic effects of ARO-HBV in healthy adult volunteers, as well as a multiple-dose escalation study to evaluate the safety, tolerability, and pharmacodynamic effects in HBV patients.

READ THE FULL RELEASE